7,376.86

+23.13

+0.31%

51,285.73

-237.37

-0.46%

24,579.42

+264.42

+1.09%

2,754.11

+24.22

+0.89%

4.8590

+0.0220

+0.45%

25.64

-2.54

-9.01%

4,074.90

-38.60

-0.94%

75,769.55

+85.15

+0.11%

Crude Oil Dec 26

90.83

+0.31

+0.34%

US Private Equity

10,772.76

+11.83

+0.11%

LSE - Delayed Quote CHF

Cosmo N.V. (0RGI.L)

56.50 -1.70 (-2.92%)

At close: November 6 at 3:06:20 PM GMT

Loading Chart for 0RGI.L

Chart Range Bar

Interval:

In partnership with ChartIQ

Cosmo Announces Positive Phase 2 Study of Rifamycin 1% Topically Acting Gel, Meeting the Primary Endpoint in Distal Ulcerative Colitis and Ulcerative Proctitis

Largest Real-World Study of the GI Genius(TM) Intelligent Endoscopy System Demonstrates Improved Adenoma Detection in Routine Clinical Practice

Cosmo Reports Double-Digit Recurring Revenue Growth in H1 2026, Advances Clascoterone 5% Topical Solution Toward Regulatory Submission, and Confirms Full-Year Guidance

Invitation to Cosmo's Half-Year 2026 Financial Results Webcast on 23 July 2026

Cosmo Welcomes the Launches of Winlevi(R) in Austria and Germany

Cosmo Welcomes the Launch of Winlevi(R) in Key European Markets by Its Partner Glenmark

Cosmo Announces SIX Ticker Symbol Change to "CMHC"

UPDATE: Phase 3 Data Support a Novel Mechanism for Male Hair Loss: Spokane Dermatologist Dr. Wm. Philip Werschler on the Significance of the Clascoterone Results

UPDATE: Phase 3 Data Support a Novel Mechanism for Male Hair Loss: Spokane Dermatologist Dr. Wm. Philip Werschler on the Significance of the Clascoterone Results

Phase 3 Data Support a Novel Mechanism for Male Hair Loss: Spokane Dermatologist Dr. Wm. Philip Werschler on the Significance of the Clascoterone Results

Phase 3 Data Support a Novel Mechanism for Male Hair Loss: Spokane Dermatologist Dr. Wm. Philip Werschler on the Significance of the Clascoterone Results

Cosmo NV (CMOPF) Half Year 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Cosmo NV (CMOPF) Half Year 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Phase III 12-Month Data for Clascoterone 5% Topical Solution Confirm Positive Safety for Chronic Use and Continued Hair Growth, both of which are Statistically Significant

Mobilize your Website

View Site in Mobile | Classic

Share by: